Actinium-225 is a targeted and highly-potent alpha emitter that holds promise for patients who do not respond to lutetium-177 ...

In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to radionuclide therapy targeting prostate specific membrane antigen (PSMA) with the ...

MELBOURNE, Australia & INDIANAPOLIS & KETTERING, Ohio--(BUSINESS WIRE)--Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has commenced a collaboration with Kettering ...

Research presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) describes a new class of radiopharmaceuticals, named radiohybrids (rh), that offer a ...

Prevalence of residual tumor in the prostate after contemporary systemic therapy. Effect of VERU-111, a novel oral inhibitor of α and β tubulin, on tumor growth in the human castration-resistant ...

Application error: a client-side exception has occurred (see the browser console for more information).

In an interview with CURE®, Dr. Phillip J. Koo defines what theranostics is, discusses the treatment’s potential and answers questions patients may have regarding its safety. There’s a tremendous ...

Telix Pharmaceuticals excels in radiopharmaceuticals, with strong revenue growth driven by imaging products like Illuccix and promising therapeutic programs in development. TLX's key imaging projects ...

SYDNEY, Australia, March 03, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic ...

The University of California's two nationally ranked medical centers, UCSF and UCLA, and their nuclear medicine teams have obtained approval from the U.S. Food and Drug Administration to offer a new ...